KLK3, kallikrein related peptidase 3, 354

N. diseases: 358; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE The PSMA positivity rate for PC was significantly higher in dPET/CT for the lowest PSA values (PSA < 2.0 ng/ml, p < 0.05). 31792572 2020
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. 31730876 2020
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE <sup>68</sup>Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 30350010 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA. 30788590 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. 30987843 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. 30487644 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE The aim of our study was to evaluate correlations between PSA levels and standardized uptake values (SUV) in patients with recurrent prostate cancer. 31568268 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE The primary outcome measure was to determine the relationship between pre-scan PSA and the probability of identifying PSMA-avid disease suggestive of recurrent prostate cancer. 31363165 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE 68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level. 30540597 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE <b>Conclusion:</b> We have shown, in a large cohort of patients, that 68Ga-PSMA-11 PET/CT is a sensitive tool for restaging PC and has a high detection efficacy, even in patients with very low PSA levels (<0.2 ng/ml). 31693724 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE Detection of recurrent prostate cancer using F-fluciclovine PET/CT is possible in patients with low but rising PSA levels of 1 ng/mL or less. 30589673 2019
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Trigger PSA is an important risk factor for positive findings of Choline PET/CT and the detection rate of Choline PET/CT for recurrent prostate cancer increased in parallel with raises in PSA-values. 29581869 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Thirty patients (median prostate-specific antigen [PSA: 11.8 ng/mL]) with suspected recurrent prostate cancer following definitive treatment underwent <sup>11</sup>C-choline PET/CT and conventional imaging, including pelvic MRI, contrast-enhanced chest, abdomen, and pelvic CT, and bone scintigraphy. 30210954 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells in patients with PSA-recurrent prostate cancer. 29534736 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. 30124601 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE Fluciclovine, also known as anti-1-amino-3-[<sup>18</sup>F]-fluorocyclobutane-1-carboxylic acid (Axumin), is a new PET radiotracer approved by the Food and Drug Administration in 2016 for the detection of suspected recurrent prostate cancer with elevated prostate-specific antigen levels. 30077749 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE Our data show that <sup>68</sup>Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels <0.5 ng/mL. 29032394 2018
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE In addition, to determine the success of <sup>111</sup> In-PSMA-RGS with regard to postoperative prostate-specific antigen (PSA) responses, PCa-specific treatment-free survival rates and postoperative complication rates. 27862863 2017
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Further optimization of the tumor-to-background contrast might significantly enhance the sensitivity of PET/CT imaging and the probability of detecting recurrent prostate cancer at low PSA values. 28787147 2017
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level. 28319497 2017
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP. 27597240 2017
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 GeneticVariation disease BEFREE We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≥50% PSA declines, the primary endpoint. 25431127 2015
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 GeneticVariation disease BEFREE Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. 23946329 2013
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 Biomarker disease BEFREE We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy. 18471323 2008
CUI: C0278838
Disease: Prostate cancer recurrent
Prostate cancer recurrent
0.100 AlteredExpression disease BEFREE PCA3 and PSA mRNAs were undetectable in postprostatectomy specimens except for one man with recurrent prostate cancer.Assay interrun CVs were < or =12%. 16627561 2006